Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danicopan PK and Safety in Renal Impairment
NCT04935294Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of danicopan in paroxysmal nocturnal hemoglobinuria (PNH) and Complement 3 glomerulopathy (C3G) (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Participants With Treatment-emergent Adverse Events. Started Jan 2018; status: completed.
02
Drugs
danicopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)Complement 3 glomerulopathy (C3G)
Beyond the preview
Go deeper on NCT04935294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04935294.